Optimizing stroke prevention in atrial fibrillation: Better adherence and compliance from patients and physicians leads to better outcomes

Europace

Volumn 17, Issue 4, 2015, Pages 507-508

  Potpara, Tatjana S ^a,b   Lane, Deirdre A ^c   Lip, Gregory Y H ^a,c,d  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; RIVAROXABAN;

BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG DOSE REGIMEN; EDITORIAL; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTOCOL COMPLIANCE; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT DURATION; ATRIAL FIBRILLATION; DRUG ADMINISTRATION; FEMALE; MALE; REGISTER; STROKE; TREATMENT WITHDRAWAL; UTILIZATION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; REGISTRIES; RIVAROXABAN; STROKE; THROMBOEMBOLISM; WITHHOLDING TREATMENT;

EID: 84926678676     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv041     Document Type: Editorial

References (17)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
2. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22.
3. Potpara TS, LaneDA. Diving to the foot of an iceberg: the SEARCH for undiagnosed atrial fibrillation. Thromb Haemost 2014;112:1-3.
4. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2015;17:194-206.
5. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14.
6. Bottoni N, Tritto M, Ricci R, Accogli M, Di Biase M, Iacopino S et al. Adherence to guidelines for atrial fibrillation management of patients referred to cardiology departments: Studio Italiano multicentrico sul Trattamento della Fibrillazione Atriale (SITAF). Europace 2010;12:1070-7.
7. Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace 2010;12:779-84.
8. Potpara TS, Polovina MM, MujovicNMet al. Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. Patient Prefer Adherence 2013;7:835-42.
9. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharm Des 2015;21:533-43.
10. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23.
11. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107.
12. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9.
13. Camm AJ, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FDR. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 2015: EUPC-D-15-00066.
14. Beyer-Westendorf J, Frster K, Ebertz F et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:524-32.
15. Laliberte F, NelsonWW, Lefebvre P et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Therapy 2012;29:675-90.
16. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125:2298-307.
17. Berti D, Hendriks JM, Brandes A et al. A proposal for interdisciplinary, nursecoordinated atrial fibrillation expert programmesas away to structure daily practice. Eur Heart J 2013;34:2725-30.